IL2 and Miyoshi myopathy: Most of the circulating pomalidomide metabolites were tested for direct inhibition of MM cell proliferation and for immunomodulatory activity (elevation of T cell IL-2 production and inhibition of PBMC TNF-α production) and were at least 26-fold less active in these assays.